Tenaya Therapeutics Inc. announced its third quarter 2025 financial results and provided a business update. The company highlighted new data from the MyPEAK-1 trial, showing consistent, deeper, and durable improvement in hypertrophy measures for Cohort 1 patients. Initial data from TN-201 Cohort 2 demonstrated early dose-responsive increases in TN-201 transduction and MyBP-C protein expression. Dosing was completed in Cohort 2 of the RIDGE-1 trial of TN-401 for PKP2-associated ARVC, with Cohort 1 data expected to be presented in the fourth quarter. Additionally, Tenaya presented preclinical data at the American Heart Association Scientific Sessions, indicating significant and durable improvement of cardiac function in a pig model of ischemic heart failure using a proprietary in vivo reprogramming cocktail. The company held a webcast conference call to review these updates with analysts and investors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-273230), on November 10, 2025, and is solely responsible for the information contained therein.
Comments